Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRESTIGE-AF
2018-002176-41Phase 3Completed
- Sponsor
- Imperial College London
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of apixaban, dabigatran, edoxaban and rivaroxaban in Atrial fibrillation (AFib) (2 arms), sponsored by Imperial College London. Primary endpoints: Ischaemic stroke and Recurrent intracerebral hemorrhage / recurrent brain bleed. Started Mar 2019; status: completed.
02
Drugs
apixabandabigatranedoxabanrivaroxaban
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2018-002176-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002176-41.